New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers

July 02, 2008

The first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, shows promising anticancer results in mice, report researchers from Children's Hospital Boston. Findings were published online on June 29 by the journal Nature Biotechnology.

Because it is nontoxic and can be taken orally, the drug, called Lodamin, may be useful as a preventive therapy for patients at high risk for cancer or as a chronic maintenance therapy for a variety of cancers, preventing tumors from forming or recurring by blocking the growth of blood vessels to feed them. Lodamin may also be useful in other diseases that involve aberrant blood-vessel growth, such as age-related macular degeneration and arthritis.
Developed by Ofra Benny, PhD, in the Children's laboratory of the late Judah Folkman, MD, Lodamin is a novel slow-release reformulation of TNP-470, a drug developed nearly two decades ago by Donald Ingber, MD, PhD, then a fellow in Folkman's lab, and one of the first angiogenesis inhibitors to undergo clinical testing. In clinical trials, TNP-470 suppressed a surprisingly wide range of cancers, including metastatic cancers, and produced a few complete remissions. Trials were suspended in the 1990s because of neurologic side effects that occasionally occurred at high doses, but it remains one of the broadest-spectrum angiogenesis inhibitors known.

Lodamin appears to retain TNP-470's potency and broad spectrum of activity, but with no detectable neurotoxicity and greatly enhanced oral availability. While a number of angiogenesis inhibitors, such as Avastin, are now commercially available, most target only single angiogenic factors, such as VEGF, and they are approved only for a small number of specific cancers. In contrast, Lodamin prevented capillary growth in response to every angiogenic stimulus tested. Moreover, in mouse models, Lodamin reduced liver metastases, a fatal complication of many cancers for which there is no good treatment.
"The success of TNP-470 in Phase I and II clinical trials opened up anti-angiogenesis as an entirely new modality of cancer therapy, along with conventional chemotherapy, radiotherapy and surgical approaches," says Ingber, now co-interim director of the Vascular Biology Program at Children's.

TNP-470 was first reformulated several years ago by Ronit Satchi-Fainaro, PhD, a postdoctoral fellow in Folkman's lab, who attached a large polymer to prevent it from crossing the blood-brain barrier (Cancer Cell, March 2005). That formulation, Caplostatin, has no neurotoxicity and is being developed for clinical trials. However, it must be given intravenously.

Benny took another approach, attaching two short polymers (PEG and PLA) to TNP-470. Experimenting with polymers of different lengths, she found a combination that formed stable, "pom-pom"-shaped nanoparticles known as polymeric micelles, with TNP-470 at the core. The polymers (both FDA-approved and widely used commercially) protect TNP-470 from the stomach's acidic environment, allowing it to be absorbed intact when taken orally. The micelles reach the tumor, react with water and break down, slowly releasing the drug.

Tested in mice, Lodamin had a significantly increased half-life, selectively accumulated in tumor tissue, blocked angiogenesis, and significantly inhibited primary tumor growth in mouse models of melanoma and lung cancer, with no apparent side effects when used at effective doses. Subsequent tests suggest that Lodamin retains TNP-470's unusually broad spectrum of activity. "I had never expected such a strong effect on these aggressive tumor models," Benny says.

Notably, Lodamin accumulated in the liver without causing toxicity, preventing liver metastases and prolonging survival. "This was one of the most surprising things I saw," says Benny. "When I looked at the livers of the mice, the treated group was almost clean. In the control group you couldn't recognize the livers -- they were a mass of tumors."

TNP-470 itself has an interesting history. It was derived from fumagillin, a mold with strong anti-angiogenic effects that Ingber discovered accidentally while culturing endothelial cells (the cells that line blood vessels). Ingber noticed that in certain dishes -- those contaminated with the mold -- the cells changed their shape by rounding, a behavior that inhibits capillary cell growth. Ingber cultured the fungus, disregarding lab policy, which called for contaminated culture to be discarded immediately. He and Folkman later developed TNP-470, a synthetic analog of fumagillin, with the help of Takeda Chemical Industries in Japan (Nature, December 1990). It has shown activity against dozens of tumor types, though its mechanism of action is only partly known.

"It's been an evolution," says Benny, "from fumagillin to TNP-470 to Caplostatin to Lodamin."

Lodamin and Caplostatin have been optioned for clinical development by SynDevRx, Inc., a Cambridge, Mass.-based biotechnology company. Benny, who is from Israel, coined the name Lodamin from Hebrew. ("Lo dam" means "no blood.") She continues to study Lodamin's effects in other animal models of cancer, and in macular degeneration with Robert D'Amato, MD, PhD, in the Vascular Biology program.

Folkman, the Lodamin paper's senior author, died unexpectedly in January, just days after Benny submitted the paper for publication. The paper, a part of his legacy, is dedicated to his memory.

The study was supported in part by the U.S. Department of Defense.

Children's Hospital Boston

---

---

	Foods to Fight Cancer: Essential foods to help prevent cancer by Richard Beliveau (Author) Detailing the key foods that have been medically shown to be beneficial in both preventing and fighting cancer, this is the must-have resource for anyone looking to get healthy and stay that way. AUTHOR BIO: Richard Béliveau, PhD, a leading authority in cancer research, holds the Chair in the Prevention and Treatment of Cancer at the Université du Quebec à Montréal, where he is a professor of biochemistry. Denis Gingras, PhD, in an oncology researcher at the Centre de cancérologie Charles-Bruneau.
	Angiogenesis: Biology and Pathology (Cold Spring Harbor Perspectives in Medicine) by Michael Klagsbrun (Editor), Patricia D'Amore (Editor) The generation of the vascular system is an important part of embryonic development. Formation of new blood vessels that supply growing tumors with nutrients is also an essential aspect of cancer progression. Work pioneered by researchers such as Judah Folkman, to whom this book is dedicated, has illuminated the mechanisms by which new blood vessels are produced and the vascular system as a whole is patterned. The contributors to this volume review our understanding of the mechanisms of angiogenesis, it s role in cancer and other pathologies, as well as therapeutic approaches that target angiogenesis to combat these diseases.
	Dr. Folkman's War: Angiogenesis and the Struggle to Defeat Cancer by Robert Cooke (Author), C. Everett Koop (Foreword) In 1961, twenty-eight-year-old Dr. Judah Folkman saw something while doing medical research in a United States navy lab that gave him the first glimmering of a wild, inspired hunch. What if cancerous tumors, in order to expand, needed to trigger the growth of new blood vessels to feed themselves? And if that was true, what if a way could be found to stop that growth? Could cancers be starved to death? Dr. Folkman had ample reason to be self confident — second in his class at Harvard Medical School, he was already considered one of the most promising doctors of his generation. But even he never guessed that his idea would eventually grow into a multibillion-dollar industry that is now racing through human trials with drugs that show unparalleled promise of being able to control...
	Tumor Angiogenesis by Francis S. Markland (Editor), Stephen Swenson (Editor), Radu Minea (Editor) Covering one of the most important research topics in cancer biology, this is an ideal ready reference for oncologists, cell biologists, pharmaceutists, pathologists, molecular biologists, internists, and researchers working in the pharmaceutical industry. Following an introduction that provides an overview of tumor angiogenesis, the book goes on to look at mechanisms of angiogenesis and lymphangiogenesis, signal transduction, therapeutic approaches in combination with established treatments, and concludes with a section on imaging and biomarkers in angiogenesis.
	Angiogenesis: An Integrative Approach from Science to Medicine by William D. Figg (Editor), Judah Folkman (Editor) Dr. Judah Folkman, father of angiogenesis , (1933-2008) was the Director of the Vascular Biology Program, Andrus Professor of Pediatric Surgery, and Professor of Cell Biology at Harvard University's Boston Children's Hospital. In the 1971 issue of The New England Journal of Medicine, he proposed the theory that tumor growth is angiogenesis dependent. This premise was the basis of this field of research and has become the focus of scientists worldwide. Because of Folkman's discovery and research, the possibilities of antiangiogenic and angiogenic therapy have broadened beyond cancer to many noncancerous diseases. This book represents the first collection in a volume of which Dr. Folkman is co-editor. Dr. Folkman authored nearly 400 original papers and more than 100 book chapters. Dr....
	The H-Wave® Device Induces NODependent Augmented Microcirculation and Angiogenesis, Providing Both Analgesia and Tissue Healing in Sports Injuries (The Physician and Sportsmedicine) by JTE Multimedia Abstract: The hypothesis that the H-Wave® device (Electronic Waveform Lab, Inc., Huntington Beach, CA), a small-diameter fiber stimulator, is a paradigm shift of electrotherapeutic treatment of pain associated with human neuropathies and sports injuries is based on a number of its properties. The primary effect of H-Wave® device stimulation (HWDS) is the stimulation of "red-slow-twitch" skeletal muscle fibers. The authors propose, based on the unique waveform, that the H-Wave® device specifically and directly stimulates the small smooth muscle fibers within the lymphatic vessels ultimately leading to fluid shifts and reduced edema. In unpublished rat studies, it has been observed that HWDS induces protein clearance. The H-Wave® device was designed to stimulate an ultra low frequency...
	History of Research on Tumor Angiogenesis by Domenico Ribatti (Author) In 1971, J. Folkman published in the “New England Journal of Medicine” a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that the resulting tumor neovascularization could conceivably be prevented or interrupted by angiogenesis inhibitors. Solid and haematological tumors consist of an avascular and a subsequent vascular phase. Assuming that this depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumor growth and metastasis. Beginning in the 1980’s, the biopharmaceutical industry began exploiting the field of...
	Retinal and Choroidal Angiogenesis by John Penn (Editor) Retinal and choroidal angiogenesis are the leading causes of irreversible vision loss in developed countries. For this reason, ocular angiogenesis is an intensely studied process, and the field is advancing at an astounding pace. It has become increasingly difficult to manage the vast amount of information generated by the growing group of interested investigators, thus a resource is needed that distills and summarizes our progress to date. Retinal and Choroidal Angiogenesis provides a comprehensive, in-depth review of our current understanding of the growth of blood vessels within the eye. Renowned academic scientists, pharmaceutical scientists, and clinician-scientists have contributed chapters identifying the cellular and molecular mechanisms of retinal and choroidal angiogenesis;...
	Ocular Angiogenesis: Diseases, Mechanisms, and Therapeutics (Ophthalmology Research) by Joyce Tombran-Tink (Editor), Colin J. Barnstable (Editor) Leading academic and pharmaceutical researchers and clinicians from many disciplines synthesize and summarize current clinical and basic knowledge concerning abnormal growth of blood vessels in the eye, the cause of major neovascular eye diseases. The authors also identify and assess the most promising approaches with potential for commercial exploitation and discuss the challenges encountered in developing therapeutics for ocular neovascular diseases. Highlights include illuminating chapters on gene therapy and novel drug delivery systems and excellent summaries of the newest therapeutic approaches.
	Angiogenesis: In Vitro Systems, Volume 443 (Methods in Enzymology) by David A. Cheresh (Editor) Angiogenesis is the growth of new blood vessels and is an important natural process in the body. A healthy body maintains a perfect balance of angiogenesis modulators. In many serious disease states, however, the body loses control over antiogenesis. Diseases that are angiogensis-dependent result when blood vessels either grow excessively or insufficiently. * Tried-and-tested techniques written by researchers that developed them, used them, and brought them to fruition * Provides the "builder's manual" for essential techniques--a one-stop shop that eliminates needless searching among untested techniques * Includes step-by-step methods for understanding the cell and molecular basis of wound healing, vascular integrin...